Inside a healthy human cell, nearly two metres of DNA must be compacted into a microscopic nucleus. This is achieved by wrapping DNA around histone proteins to form chromatin, which is then folded through several levels of organization. Chromatin is arranged into chromosomes occupying distinct nuclear territories, while regions with similar activity are grouped into compartments. Within these compartments, topologically associating domains, or TADs, bring neighbouring regulatory elements into preferred physical neighbourhoods. Even more precise contacts, known as chromatin loops, can connect gene promoters with distant enhancers that control their activity. Together, these structures help determine how the genome operates in space and time.

The review describes cancer-associated remodelling at each of these scales. Changes in chromosome structure can alter how entire genomic regions are positioned within the nucleus. Shifts between active and inactive chromatin compartments can modify the overall transcriptional state of large DNA segments. Disruption of domain boundaries may allow enhancers to communicate with genes that they would normally be unable to reach, while new or rearranged loops can establish abnormal regulatory connections. These events may activate oncogenes, silence tumour-suppressor genes or change the way cancer cells respond to signals from their environment.

One important source of three-dimensional disruption is genetic mutation. Structural variants such as deletions, duplications, inversions and translocations can physically rearrange the DNA sequences that form regulatory landscapes. A mutation does not need to occur inside a gene to have a powerful effect. If it removes a boundary separating an enhancer from an unrelated gene, for example, the enhancer may become available to the wrong promoter. Similarly, a rearrangement can place a powerful regulatory element next to an oncogene, creating persistent gene activation. In this way, the biological consequence of a genetic alteration may depend not only on the sequence that is changed, but also on the spatial relationships that are created or destroyed.

Cancer cells also reshape chromatin through epigenetic mechanisms, which alter gene activity without changing the underlying DNA sequence. Chemical modifications of histones, DNA methylation and the action of chromatin-remodelling complexes can change how tightly DNA is packaged and which regulatory regions are accessible to transcription factors. These changes can weaken normal boundaries, reorganize contacts between enhancers and promoters, or convert silent chromatin into an active state. Because epigenetic marks are often reversible, they may provide cancer cells with a degree of flexibility, allowing different cell populations within the same tumour to adopt distinct regulatory programmes.

The relationship between genome alterations and chromatin architecture is therefore circular rather than one-directional. Genetic and epigenetic changes can remodel three-dimensional structure, but the structure itself may also influence where alterations arise and how strongly they affect the cell. Regions of open, actively transcribed chromatin may experience different forms of replication stress or DNA damage from compact, inactive regions. The physical proximity of distant DNA segments may also increase the likelihood that breaks occurring in separate locations will be misrepaired together. A spatially organized genome could thus help shape the distribution of mutations and rearrangements that cancer evolution selects.

This feedback may help explain why some abnormalities become especially powerful during tumour development. A genetic alteration that appears modest when considered only at the sequence level may have a much larger effect if it changes a domain boundary or creates a new loop. Conversely, the same mutation could produce different outcomes in different cellular contexts, depending on the existing chromatin landscape and the regulatory elements available nearby. The review emphasizes that oncogenic capacity can sometimes be understood only by analysing the interaction between DNA sequence, epigenetic state and three-dimensional conformation.

The picture becomes even more complex inside individual tumours. Cancer is not usually a uniform population of identical cells; instead, it contains subclones with different mutations, epigenetic profiles and functional states. Their chromatin architectures may differ as well. Some cells may maintain highly active regulatory circuits that support rapid proliferation, while others may occupy more dormant or treatment-resistant states. This three-dimensional heterogeneity could influence how tumours evolve, spread and respond to therapy. A treatment that eliminates cells with one chromatin configuration might leave behind a subpopulation whose regulatory architecture enables survival and later regrowth.

Mapping these structures could eventually provide new approaches to cancer diagnosis and treatment. Technologies that measure chromatin contacts, such as chromosome-conformation methods, can reveal interactions across the genome that are invisible to conventional genetic tests. When combined with sequencing, transcriptomics and epigenomic profiling, these approaches may help identify abnormal enhancer–gene connections, disrupted domain boundaries or tumour-specific regulatory circuits. Such information could improve the classification of cancers and expose vulnerabilities that are not apparent from mutations alone. Therapies might one day target the proteins that establish or maintain harmful chromatin contacts, or exploit the dependence of tumour cells on particular three-dimensional configurations.

The authors present chromatin three-dimensional remodelling as both a cause and a consequence of oncogenic change. This view expands the definition of the cancer genome beyond a linear sequence of bases and toward a dynamic system in which location, accessibility and physical contact are essential parts of gene regulation. Major questions remain, including how stable abnormal architectures are across tumour cells, how they change during metastasis and treatment, and whether they can be measured reliably in clinical samples. Yet the emerging principle is clear: to understand why a cancer behaves as it does, researchers may need to read not only the genome’s letters, but also the three-dimensional shape in which those letters are folded.

Subject of Research: The role of three-dimensional chromatin architecture in cancer development, tumour heterogeneity, oncogenic regulation and potential diagnosis and therapy.

Article Title: Origins and consequences of oncogenic 3D chromatin remodelling

Article References: Franceschini, G.M., Georgakopoulou, K., Ciriello, G. et al. “Origins and consequences of oncogenic 3D chromatin remodelling.” Nature Reviews Cancer (2026). https://doi.org/10.1038/s41568-026-00969-1

Image Credits: AI Generated

DOI: 10.1038/s41568-026-00969-1

Keywords: Cancer biology, chromatin architecture, 3D genome, gene regulation, epigenetics, oncogenes, tumour suppressors, chromatin loops, genomic rearrangements, cancer heterogeneity, precision medicine

mTOR is a central signaling hub that controls cell growth, protein production, nutrient use and survival. In healthy cells, the pathway responds to signals such as growth factors and energy availability. In kidney cancer, however, abnormal activation of mTOR can help tumors grow rapidly and tolerate hostile conditions. Drugs that inhibit mTOR are designed to interrupt this growth program, and they have become an important component of treatment for advanced renal malignancies. Yet the benefits are often limited by resistance. Some tumor cells survive initial therapy, adapt to the blocked pathway and resume proliferation, leaving clinicians with a familiar problem: a treatment that works biologically but loses effectiveness as the cancer evolves.

The new study identifies SPOP-mediated ubiquitination of ZMYND8 as a key event in that adaptation. Ubiquitination is a molecular tagging process in which one protein, acting through an enzyme system, attaches the small protein ubiquitin to another protein. These tags can mark a molecule for destruction by the proteasome, alter its location within the cell or change the way it interacts with other proteins and DNA. SPOP, short for speckle-type POZ protein, functions as a substrate-recognition factor in a ubiquitin ligase complex. Its role is to identify selected proteins and help determine their cellular fate. According to the study, SPOP targets ZMYND8, changing the abundance or behavior of this chromatin-associated regulator in a way that favors survival during mTOR inhibition.

ZMYND8 is a multifunctional nuclear protein that can connect chromatin, transcriptional machinery and DNA damage-response systems. Chromatin is the highly organized material formed when DNA is wrapped around histone proteins and folded with the help of additional regulators. The arrangement of chromatin determines which genes are accessible for transcription and which remain silent. By influencing this arrangement, ZMYND8 can affect broad gene-expression programs rather than a single isolated pathway. The findings therefore suggest that mTOR inhibitor resistance may arise through an epigenetic and structural reprogramming of the cancer cell, allowing it to activate alternative survival instructions even when the main growth pathway is pharmacologically suppressed.

The most striking element of the research is the connection to biomolecular phase separation. Inside cells, many proteins and nucleic acids do not simply float in a uniform solution. They can condense into dynamic, membrane-free compartments often described as biomolecular condensates. These structures form when molecules with compatible interaction surfaces cluster together, creating concentrated environments for transcription, RNA processing, signaling or DNA repair. The process resembles the separation of oil and water, but at the molecular scale and under tightly regulated cellular conditions. Phase separation can be reversible and highly responsive, making it a powerful mechanism for rapidly organizing biochemical reactions.

The study proposes that ZMYND8 is excluded from particular phase-separated nuclear condensates in mTOR inhibitor-resistant kidney cancer cells. That exclusion is potentially decisive. If ZMYND8 cannot enter or remain within the condensates where gene regulation is organized, it may lose access to the DNA regions, cofactors or transcriptional complexes that normally support its regulatory functions. SPOP-mediated ubiquitination appears to promote this altered distribution, creating a nuclear environment in which the protein is physically separated from the molecular assemblies that would otherwise oppose resistance. In this model, the cancer cell is not merely switching genes on and off; it is changing where regulatory reactions take place.

This mechanism offers a possible explanation for why blocking mTOR alone may produce only a temporary response. When the pathway is inhibited, tumor cells experience a sudden reduction in growth-promoting signals and biosynthetic activity. Cells that can rapidly reorganize transcription and chromatin may gain a survival advantage. By modifying ZMYND8 and controlling its access to phase-separated compartments, SPOP could help establish a new gene-expression state that supports persistence. The resulting resistance program may include changes in proliferation, metabolism, stress tolerance and DNA repair, although the exact downstream genes and cellular dependencies will determine how broadly the mechanism applies across kidney cancer subtypes.

The findings also raise the possibility of a new therapeutic strategy: attack the resistance architecture rather than simply increasing the dose of the original mTOR inhibitor. One approach could involve disrupting the interaction between SPOP and ZMYND8, preventing the ubiquitination event that alters ZMYND8 behavior. Another could target the molecular interactions responsible for condensate formation or exclusion, restoring ZMYND8 to the nuclear compartments where it can exert its regulatory effects. Such strategies would require considerable caution. Phase-separated condensates are involved in normal gene control and cellular maintenance, so broadly disturbing them could damage healthy tissue. The challenge will be to identify cancer-specific interactions or condensates that can be manipulated without producing unacceptable toxicity.

The work may also influence how researchers think about drug resistance more generally. Resistance is often investigated through the lens of genetic mutations, such as alterations in drug targets or signaling proteins. Those changes remain important, but the SPOP–ZMYND8 pathway illustrates how cancer cells can exploit protein modification, chromatin organization and the physical chemistry of the nucleus without relying exclusively on a new mutation in the drug target itself. This layered form of adaptation could help explain why tumors with apparently similar genetic profiles respond differently to the same therapy. It also suggests that future treatment decisions may benefit from measuring protein localization, ubiquitination states and condensate behavior alongside DNA sequence.

For patients, the research does not yet represent a ready-made treatment, but it provides a sharper map of a problem that has limited the durability of mTOR-targeted therapy. The study’s central message is that resistance can be built through molecular geography: a protein’s position inside the cell may matter as much as its presence or absence. By linking SPOP activity, ZMYND8 ubiquitination and phase-separation exclusion, the researchers describe a mechanism that connects biochemical tagging to nuclear organization and, ultimately, tumor survival. The next step will be to determine whether this pathway can be safely manipulated in animal models and clinical samples, and whether combining mTOR inhibitors with agents aimed at the SPOP–ZMYND8 axis can prevent resistant kidney cancer cells from finding a way around treatment.

Subject of Research: SPOP-mediated ZMYND8 ubiquitination and phase-separation exclusion as a mechanism of mTOR inhibitor resistance in kidney cancer.

Article Title: SPOP-mediated ZMYND8 ubiquitination and phase separation exclusion drives mTOR inhibitor resistance in kidney cancer.

Article References: Tang, B., Sun, R., Shao, J. et al. “SPOP-mediated ZMYND8 ubiquitination and phase separation exclusion drives mTOR inhibitor resistance in kidney cancer.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-77043-9

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77043-9

Keywords: kidney cancer, mTOR inhibitors, drug resistance, SPOP, ZMYND8, ubiquitination, phase separation, biomolecular condensates, chromatin regulation, cancer biology